- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03421015
Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution (CHRU-WCMC)
November 6, 2019 updated by: University Hospital, Lille
Genomic Analysis in Localized or Locally Advanced Prostate Cancer. Identification of Biomarkers Predictive of Biochemical or Metastatic Recurrence
Developing a genetic study on localized or locally advanced prostate cancer. The aim of the study is to identify genomic alteration predictive of metastatic recurrence in the context of primary heterogeneity, by using the next generation sequencing (NGS) techniques.
Identifying such biomarkers may be useful to detect a higher relapse risk, and thus lower the mortality rate.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
84
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Arnauld Villers, MD,PhD
- Phone Number: +33 3 20 44 42 35
- Email: arnauld.villers@chru-lille.fr
Study Locations
-
-
-
Lille, France
- Recruiting
- Hôpital Claude Huriez, CHRU
-
Principal Investigator:
- Arnaud Villers, MD,PhD
-
Sub-Investigator:
- Thomas Caes, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients managed by radical prostatectomy for prostate cancer
Description
Inclusion Criteria:
- Patients managed by radical prostatectomy for prostate cancer between 2000 and 2016.
- Follow up > 6 years
- Negative pre surgical extension assessment
- Prognostic Grade Groups (OGG) III-IV-V
- Biochemical recurrence defined by 2 consecutive PSA rises ≥ 0,2 ng/mL
- Metastasis positive imaging
Exclusion Criteria:
- Neoadjuvant therapy
- Follow up < 6 years
- Prognostic Grade Groups (PGG) I-II
- Biochemical recurrence with metastasis negative imaging
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
case group
patients with biochemical recurrence and positive imaging (case group)
|
Control Group
patients without biochemical recurrence (control group)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The genetic alteration frequencies of TMPRSS2-ERG gene fusion
Time Frame: Baseline
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of amplification of proto-oncogenes (MYC, AR, PIK3CA),
Time Frame: Baseline
|
Baseline
|
Frequency of mutations or deletions of tumor suppressor genes (PTEN, TP53, NKX3-1),
Time Frame: Baseline
|
Baseline
|
Frequency of point mutations modifying protein function (SPOP)
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Arnauld Villers, MD,PhD, University Hospital, Lille
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2017
Primary Completion (Anticipated)
July 1, 2020
Study Completion (Anticipated)
July 1, 2020
Study Registration Dates
First Submitted
January 29, 2018
First Submitted That Met QC Criteria
January 29, 2018
First Posted (Actual)
February 5, 2018
Study Record Updates
Last Update Posted (Actual)
November 7, 2019
Last Update Submitted That Met QC Criteria
November 6, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017_12
- 2017-A01870-53 (Other Identifier: ID-RCB number, ANSM)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
MacroGenicsRecruitingCastration-Resistant Prostatic Cancer | Androgen-Independent Prostatic Cancer | Androgen-Insensitive Prostatic Cancer | Androgen-Resistant Prostatic Cancer | Hormone Refractory Prostatic CancerSpain, Australia, Korea, Republic of, United States, France, Italy, Belgium, United Kingdom, Poland
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States